Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Redwire Corporation (RDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Redwire Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Redwire Corporation trades at $10.02 (market cap $2.43B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 16.4× Redwire Corporation's market cap, and Redwire Corporation is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | RDW | |
|---|---|---|
Market Cap | $39.89B | $2.43B |
Sector | Health | Technology |
52-Week High | $491.22 | $25.90 |
52-Week Low | $278.09 | $5.06 |
Enterprise Value | $38.15B | $2.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
RDW trades at $10.18, down 2.77% today amid bearish technical signals despite bullish analyst sentiment. The stock shows weak fundamentals with a -80.9% net income margin and three consecutive quarterly EPS misses. Recent news highlights volatility driven by SpaceX's market impact and RDW's capital raising activities, though new defense contracts provide some optimism.
The outlook remains high-risk due to persistent losses and cash burn, but analyst consensus suggests 87% upside to the $19 price target. Key risks include dilution from fundraising and intense space sector competition, requiring careful monitoring of profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
